These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
626 related articles for article (PubMed ID: 12029552)
1. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552 [TBL] [Abstract][Full Text] [Related]
2. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835 [TBL] [Abstract][Full Text] [Related]
3. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856 [TBL] [Abstract][Full Text] [Related]
4. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Dam HQ; Kim SM; Lin HC; Intenzo CM Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323 [TBL] [Abstract][Full Text] [Related]
5. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550 [TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. Silberstein EB J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976 [TBL] [Abstract][Full Text] [Related]
7. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. Morris LF; Waxman AD; Braunstein GD J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771 [TBL] [Abstract][Full Text] [Related]
8. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Park HM; Perkins OW; Edmondson JW; Schnute RB; Manatunga A Thyroid; 1994; 4(1):49-54. PubMed ID: 8054861 [TBL] [Abstract][Full Text] [Related]
9. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871 [TBL] [Abstract][Full Text] [Related]
10. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. Muratet JP; Daver A; Minier JF; Larra F J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549 [TBL] [Abstract][Full Text] [Related]
12. Thyroid stunning in clinical practice: is it a real problem? Filesi M; Colandrea M; Montesano T; D'Apollo R; Ronga G Minerva Endocrinol; 2009 Mar; 34(1):29-36. PubMed ID: 19209126 [TBL] [Abstract][Full Text] [Related]
13. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer. Gerard SK; Dam HQ Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947 [No Abstract] [Full Text] [Related]
14. Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans. Cohen JB; Kalinyak JE; McDougall IR Nucl Med Commun; 2004 Feb; 25(2):129-34. PubMed ID: 15154700 [TBL] [Abstract][Full Text] [Related]
15. Decreased uptake after fractionated ablative doses of iodine-131. Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912 [TBL] [Abstract][Full Text] [Related]
16. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458 [TBL] [Abstract][Full Text] [Related]
17. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937 [TBL] [Abstract][Full Text] [Related]
18. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241 [TBL] [Abstract][Full Text] [Related]
20. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation. Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]